Boston Scientific (BSX) CEO Michael Mahoney Buys Stock

What Happened
Michael F. Mahoney, Chairman, President & CEO and a director of Boston Scientific (BSX), acquired a total of 208,359 shares on August 3, 2026. He purchased 186,240 shares in open-market transactions at a weighted average price of $48.33 ($9,001,408) and acquired 22,119 shares in a discretionary 401(k) plan rebalancing at $48.43 ($1,071,223). Combined, the purchases cost approximately $10.07 million. These were purchases (net buys), which investors often view as a positive insider signal.

Key Details

• Transaction date: 2026-08-03; Form 4 filed: 2026-08-05 (appears filed within the normal 2-business-day window).
• Open-market purchase: 186,240 shares at a weighted average $48.33 (total $9,001,408). Price range for these trades: $47.87–$48.47 (footnote F1).
• Discretionary purchase (401(k) rebalance): 22,119 shares at $48.43 (total $1,071,223) (footnote F2).
• Total acquired: 208,359 shares for roughly $10,072,631.
• Shares owned after the transactions: not specified in the provided data.
• Footnotes: F1 explains the weighted-average price reflects multiple trades and the reporting person can provide per-trade prices on request. F2 notes the 22,119-share transaction resulted from a 401(k) plan rebalancing (discretionary).
• Filing timeliness: filed Aug 5 for Aug 3 transactions; no late-filing indication in the record provided.

Context
One transaction was an open-market purchase (direct buy), while the other was a discretionary allocation from the CEO’s 401(k) plan — the latter can reflect automated or plan-driven rebalancing rather than an ad hoc trading decision. Both are purchases; purchases by a company’s CEO are often watched by retail investors but do not by themselves prove future performance.